Financials

  • Market Capitalization 8.06 B
  • Employee 691
  • Founded 2014
  • CEO Rich Adcock
  • Website www.immunitybio.com
  • Headquarter Delaware, United States
  • FIGI BBG007T9DYW9
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-9.02
ratio cours/chiffre d'affaires
51.72

Related tickers

#NomPrix24h %7 jours %1M %1 an %Cap Boursière7 Derniers Jours
1023
TGTX
TG Therapeutics, Inc. - Common Stock
55.37 USD+0.87%-2.19%+10.43%+44.61%8.48 B USD
1033
PCVX
Vaxcyte, Inc. - Common Stock
56.45 USD+0.43%-1.31%+13.88%+33.45%8.15 B USD
1042
IMVT
Immunovant, Inc. - Common Stock
39.23 USD+1.19%+0.72%+18.13%+104.22%8.05 B USD
1061
KNSA
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
61.50 USD-0.77%-7.50%+17.82%+55.13%7.69 B USD

Nouvelles